Leukocyte adherence contributes to disruption of the blood-brain barrier during activation of mast cells

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The goal of this study was to examine the role of leukocytes in disruption of the blood-brain barrier during activation of mast cells using compound 48/80. We examined the pial microcirculation in rats using intravital fluorescence microscopy. Permeability of the blood-brain barrier (clearance of fluorescent-labeled dextran; molecular weight 10 000 daltons; FITC-dextran-10 K) was determined while suffusing with vehicle or compound 48/80 (10 or 25 μg/ml). During superfusion with vehicle (saline), clearance of FITC-dextran-10 K from pial vessels was modest and remained relatively constant during the experimental period (0.52±0.05 ml/sx10-6 at 80 min). In addition, diameter of pial arterioles remained constant (32±5 μm) while suffusing with vehicle. In contrast, topical application of compound 48/80 produced marked disruption of the blood-brain barrier to FITC-dextran-10 K. For example, suffusion with compound 48/80 (25 μg/ml) increased clearance of FITC-dextran-10 K about 4-fold to 2.26±0.25 ml/sx10-6 at 80 min. In addition, superfusion with compound 48/80 (25 μg/ml) constricted pial arterioles by 26±9% at 80 min. To determine a potential role for leukocyte adhesion to endothelium in disruption of the blood-brain barrier during suffusion with compound 48/80, we examined permeability during suffusion with compound 48/80 (25 μg/ml) in the presence of WT.3 (2 mg/kg i.v.), a monoclonal antibody directed against the functional epitope of the leukocyte adhesive glycoprotein (CD18; LFA-1β). We found that infusion of WT.3 markedly attenuated disruption of the blood-brain barrier to FITC-dextran-10 K in response to compound 48/80. The clearance of FITC-dextran-10 K during superfusion with compound 48/80 in the presence of WT.3 was 1.29±0.14 ml/sx10-6 at 80 min (P<0.05). Thus, the findings of the present study suggest that application of compound 48/80, to degranulate mast cells, activates the adhesion of leukocytes to cerebral venular endothelium which contributes to disruption of the blood-brain barrier. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)112-120
Number of pages9
JournalBrain Research
Volume869
Issue number1-2
DOIs
StatePublished - Jun 30 2000

Fingerprint

p-Methoxy-N-methylphenethylamine
Blood-Brain Barrier
Mast Cells
Leukocytes
Arterioles
Endothelium
Permeability
Lymphocyte Function-Associated Antigen-1
Microcirculation
Dextrans
Fluorescence Microscopy
Cell Adhesion
Adhesives
fluorescein isothiocyanate dextran
Epitopes
Glycoproteins
Molecular Weight
Monoclonal Antibodies

Keywords

  • Anti-CD18
  • Brain
  • CD18
  • Cerebral venule
  • Compound 48/80
  • FITC-dextran
  • Mast cell
  • Monoclonal antibody
  • WT.3

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Leukocyte adherence contributes to disruption of the blood-brain barrier during activation of mast cells. / Mayhan, William G.

In: Brain Research, Vol. 869, No. 1-2, 30.06.2000, p. 112-120.

Research output: Contribution to journalArticle

@article{cbcab5b0a36a475984275b4a9e54d503,
title = "Leukocyte adherence contributes to disruption of the blood-brain barrier during activation of mast cells",
abstract = "The goal of this study was to examine the role of leukocytes in disruption of the blood-brain barrier during activation of mast cells using compound 48/80. We examined the pial microcirculation in rats using intravital fluorescence microscopy. Permeability of the blood-brain barrier (clearance of fluorescent-labeled dextran; molecular weight 10 000 daltons; FITC-dextran-10 K) was determined while suffusing with vehicle or compound 48/80 (10 or 25 μg/ml). During superfusion with vehicle (saline), clearance of FITC-dextran-10 K from pial vessels was modest and remained relatively constant during the experimental period (0.52±0.05 ml/sx10-6 at 80 min). In addition, diameter of pial arterioles remained constant (32±5 μm) while suffusing with vehicle. In contrast, topical application of compound 48/80 produced marked disruption of the blood-brain barrier to FITC-dextran-10 K. For example, suffusion with compound 48/80 (25 μg/ml) increased clearance of FITC-dextran-10 K about 4-fold to 2.26±0.25 ml/sx10-6 at 80 min. In addition, superfusion with compound 48/80 (25 μg/ml) constricted pial arterioles by 26±9{\%} at 80 min. To determine a potential role for leukocyte adhesion to endothelium in disruption of the blood-brain barrier during suffusion with compound 48/80, we examined permeability during suffusion with compound 48/80 (25 μg/ml) in the presence of WT.3 (2 mg/kg i.v.), a monoclonal antibody directed against the functional epitope of the leukocyte adhesive glycoprotein (CD18; LFA-1β). We found that infusion of WT.3 markedly attenuated disruption of the blood-brain barrier to FITC-dextran-10 K in response to compound 48/80. The clearance of FITC-dextran-10 K during superfusion with compound 48/80 in the presence of WT.3 was 1.29±0.14 ml/sx10-6 at 80 min (P<0.05). Thus, the findings of the present study suggest that application of compound 48/80, to degranulate mast cells, activates the adhesion of leukocytes to cerebral venular endothelium which contributes to disruption of the blood-brain barrier. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Anti-CD18, Brain, CD18, Cerebral venule, Compound 48/80, FITC-dextran, Mast cell, Monoclonal antibody, WT.3",
author = "Mayhan, {William G.}",
year = "2000",
month = "6",
day = "30",
doi = "10.1016/S0006-8993(00)02376-3",
language = "English (US)",
volume = "869",
pages = "112--120",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Leukocyte adherence contributes to disruption of the blood-brain barrier during activation of mast cells

AU - Mayhan, William G.

PY - 2000/6/30

Y1 - 2000/6/30

N2 - The goal of this study was to examine the role of leukocytes in disruption of the blood-brain barrier during activation of mast cells using compound 48/80. We examined the pial microcirculation in rats using intravital fluorescence microscopy. Permeability of the blood-brain barrier (clearance of fluorescent-labeled dextran; molecular weight 10 000 daltons; FITC-dextran-10 K) was determined while suffusing with vehicle or compound 48/80 (10 or 25 μg/ml). During superfusion with vehicle (saline), clearance of FITC-dextran-10 K from pial vessels was modest and remained relatively constant during the experimental period (0.52±0.05 ml/sx10-6 at 80 min). In addition, diameter of pial arterioles remained constant (32±5 μm) while suffusing with vehicle. In contrast, topical application of compound 48/80 produced marked disruption of the blood-brain barrier to FITC-dextran-10 K. For example, suffusion with compound 48/80 (25 μg/ml) increased clearance of FITC-dextran-10 K about 4-fold to 2.26±0.25 ml/sx10-6 at 80 min. In addition, superfusion with compound 48/80 (25 μg/ml) constricted pial arterioles by 26±9% at 80 min. To determine a potential role for leukocyte adhesion to endothelium in disruption of the blood-brain barrier during suffusion with compound 48/80, we examined permeability during suffusion with compound 48/80 (25 μg/ml) in the presence of WT.3 (2 mg/kg i.v.), a monoclonal antibody directed against the functional epitope of the leukocyte adhesive glycoprotein (CD18; LFA-1β). We found that infusion of WT.3 markedly attenuated disruption of the blood-brain barrier to FITC-dextran-10 K in response to compound 48/80. The clearance of FITC-dextran-10 K during superfusion with compound 48/80 in the presence of WT.3 was 1.29±0.14 ml/sx10-6 at 80 min (P<0.05). Thus, the findings of the present study suggest that application of compound 48/80, to degranulate mast cells, activates the adhesion of leukocytes to cerebral venular endothelium which contributes to disruption of the blood-brain barrier. Copyright (C) 2000 Elsevier Science B.V.

AB - The goal of this study was to examine the role of leukocytes in disruption of the blood-brain barrier during activation of mast cells using compound 48/80. We examined the pial microcirculation in rats using intravital fluorescence microscopy. Permeability of the blood-brain barrier (clearance of fluorescent-labeled dextran; molecular weight 10 000 daltons; FITC-dextran-10 K) was determined while suffusing with vehicle or compound 48/80 (10 or 25 μg/ml). During superfusion with vehicle (saline), clearance of FITC-dextran-10 K from pial vessels was modest and remained relatively constant during the experimental period (0.52±0.05 ml/sx10-6 at 80 min). In addition, diameter of pial arterioles remained constant (32±5 μm) while suffusing with vehicle. In contrast, topical application of compound 48/80 produced marked disruption of the blood-brain barrier to FITC-dextran-10 K. For example, suffusion with compound 48/80 (25 μg/ml) increased clearance of FITC-dextran-10 K about 4-fold to 2.26±0.25 ml/sx10-6 at 80 min. In addition, superfusion with compound 48/80 (25 μg/ml) constricted pial arterioles by 26±9% at 80 min. To determine a potential role for leukocyte adhesion to endothelium in disruption of the blood-brain barrier during suffusion with compound 48/80, we examined permeability during suffusion with compound 48/80 (25 μg/ml) in the presence of WT.3 (2 mg/kg i.v.), a monoclonal antibody directed against the functional epitope of the leukocyte adhesive glycoprotein (CD18; LFA-1β). We found that infusion of WT.3 markedly attenuated disruption of the blood-brain barrier to FITC-dextran-10 K in response to compound 48/80. The clearance of FITC-dextran-10 K during superfusion with compound 48/80 in the presence of WT.3 was 1.29±0.14 ml/sx10-6 at 80 min (P<0.05). Thus, the findings of the present study suggest that application of compound 48/80, to degranulate mast cells, activates the adhesion of leukocytes to cerebral venular endothelium which contributes to disruption of the blood-brain barrier. Copyright (C) 2000 Elsevier Science B.V.

KW - Anti-CD18

KW - Brain

KW - CD18

KW - Cerebral venule

KW - Compound 48/80

KW - FITC-dextran

KW - Mast cell

KW - Monoclonal antibody

KW - WT.3

UR - http://www.scopus.com/inward/record.url?scp=0034733889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034733889&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(00)02376-3

DO - 10.1016/S0006-8993(00)02376-3

M3 - Article

C2 - 10865065

AN - SCOPUS:0034733889

VL - 869

SP - 112

EP - 120

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -